Table 4.
Patients’ presentation and reported outcomes at baseline by treatment strategy, N (%)
| Wait and See (n = 81) | Surgery only (n = 41) | Systemic only (n = 37) | |
|---|---|---|---|
| Mean age [years] ± SD | 44.3 ± 15.17 | 41.8 ± 14.94 | 47.7 ± 10.44 |
|
Time since diagnosis primary tumor [months] median (Q1, Q3) |
34.3 (13.8–77.9) |
6.7 (1.2–59.8) |
32.1 (18.2–89.6) |
| Treatment before baseline | |||
| Therapy-naïve | 11 (13.6) | 16 (39.0) | – |
| Surgery only | 47 (58.0) | 20 (48.8) | 7 (18.9) |
| Systemic only | 2 (2.5) | – | 9 (24.3) |
| Multimodal treatment | 21 (25.9) | 5 (12.2) | 21 (56.8) |
| Admission status | |||
| Primary diagnosis | 47 (58.0) | 27 (65.9) | 19 (51.4) |
| Recurrent diseases | 34 (42.0) | 14 (34.1) | 18 (48.6) |
| Indication MRI closest to baseline | |||
| Primary diagnosis | 7 (9.3) | 23 (57.5) | 4 (11.4) |
| Pre-surgery | 5 (6.7) | 8 (20.0) | 2 (5.7) |
| Regular postoperative follow-up | 43 (57.3) | 6 (15.0) | 7 (20.0) |
| Follow-up due to complaints | 15 (20.0) | 2 (5.0) | 13 (37.1) |
| Severity | |||
| Moderate | 34 (42.0) | 15 (36.6) | 12 (32.4) |
| Severe | 38 (46.9) | 20 (48.8) | 21 (56.8) |
| Not assessable | 9 (11.1) | 6 (14.6) | 4 (10.8) |
| In last 24 months prior to baseline | |||
| Any rehabilitation | 17 (26.2) | 5 (13.2) | 4 (12.5) |
|
Specialist visitsa, Median (range) |
5.0 (1.0–70.0) |
3.0 (10–27.0) |
12 (2.0–65.0) |
|
Physical therapy sessionsa, Median (range) |
18.0 (4.0–200.0) |
11.0 (1.0–100.0) |
11.5 (3.0–90.0) |
| Symptoms | |||
| Pain | 56 (69.1) | 37 (90.2) | 32 (86.5) |
| Stiffness | 36 (44.4) | 27 (65.9) | 23 (62.2) |
| Swelling | 44 (54.3) | 34 (82.9) | 19 (51.4) |
| Limited range of motion | 39 (48.1) | 31 (75.6) | 30 (81.1) |
| ≥ 3 symptoms | 31 (38.3) | 28 (68.3) | 22 (59.5) |
| Analgesics use | 8 (9.9) | 5 (12.2) | 9 (24.3) |
|
Worst stiffness NRS Mean ± SD (n = 144) |
3.4 ± 2.57 | 5.2 ± 3.14 | 5.3 ± 2.55 |
|
Worst pain NRS Mean ± SD (n = 81) |
5.0 ± 2.41 | 6.5 ± 2.27 | 5.8 ± 1.97 |
|
Pain severity score Median (Q1, Q3) (n = 147) |
2.25 (0.75–4.00) |
4.25 (1.50–6.25) |
4.25 (1.50–5.50) |
|
Pain interference score Median (Q1, Q3) (n = 146) |
1.57 (0.14–4.00) |
3.00 (1.14–5.57) |
3.00 (0.57–5.57) |
|
PROMIS-PF Median (Q1, Q3) (n = 142) |
44.43 (37.30–49.29) |
39.54 (34.95–44.42) |
39.98 (34.79–43.69) |
|
EQ-5D Index score Median (Q1, Q3) (n = 153) |
0.84 (0.67–0.89) |
0.80 (0.53–0.84) |
0.74 (0.48–0.84) |
|
EQ-5D VAS Median (Q1, Q3) (n = 154) |
79.0 (60.0–85.0) |
69.0 (60.0–80.0) |
70.0 (50.0–75.0) |
EQ-5D EuroQol 5D, MRI magnetic resonance imaging, NRS numeric rating scale, PROMIS Patient-Reported Outcomes Measurement Information System; PROMIS-PF Patient-Reported Outcome Measurement Information System Physical Functioning®, Q1 quarter 1, Q3 quarter 3, SD standard deviation, VAS visual analog scale
aBased on patients that had any